← Back to Search

Motivational Interviewing for Anhedonia (SAMI Trial)

N/A

Recruiting

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Taking 2nd generation antipsychotic medications

Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 weeks

Awards & highlights

SAMI Trial Summary

This trial will study how reduced sensitivity to social reward and pleasure impacts individuals experiencing their first-episode of psychosis. Participants will complete two social reward tasks and be randomized to motivational interviewing or a control.

Who is the study for?

This trial is for individuals aged 18-35 who have had their first psychotic episode within the last two years and are diagnosed with schizophrenia, schizophreniform, or schizoaffective disorder. They must be on second-generation antipsychotics, have an IQ over 70, speak English fluently, and have good vision with correction. Participants should not have a history of substance abuse or significant medical conditions.Check my eligibility

What is being tested?

The study tests if motivational interviewing can affect how people with social anhedonia experience social rewards. Half will receive motivational interviewing; the other half will get nutrition training as a control. Both groups perform tasks in a scanner before and after to see changes at behavioral and neural levels.See study design

What are the potential side effects?

Since this trial involves psychological interventions rather than medications, traditional side effects are not expected. However, participants may experience discomfort or stress during interviews or while performing tasks in the scanner.

SAMI Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am currently taking second-generation antipsychotic medications.

Select...

I have been diagnosed with schizophrenia or a related disorder.

Select...

I am between 18 and 35 years old.

SAMI Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Response Bias

fMRI activation levels

the number of optimal response

SAMI Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Motivational Interview InterventionExperimental Treatment1 Intervention

This arm involves three 45-minute sessions on motivational interviewing targeting sensitivity to social reward.

Group II: Active Control InterventionActive Control1 Intervention

This arm involves three 45-minute sessions on didactic training on nutrition.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Motivational Interviewing

2020

Completed Phase 3

~8850

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor

1,590 Previous Clinical Trials

2,281,510 Total Patients Enrolled

2 Trials studying Psychosis

290 Patients Enrolled for Psychosis

University of California, Los AngelesOTHER

1,532 Previous Clinical Trials

10,265,116 Total Patients Enrolled

7 Trials studying Psychosis

2,021 Patients Enrolled for Psychosis

National Institute of Mental Health (NIMH)NIH

2,786 Previous Clinical Trials

2,689,557 Total Patients Enrolled

46 Trials studying Psychosis

10,567 Patients Enrolled for Psychosis

Media Library

Motivational Interviewing Clinical Trial Eligibility Overview. Trial Name: NCT05617898 — N/A

Psychosis Research Study Groups: Motivational Interview Intervention, Active Control Intervention

Psychosis Clinical Trial 2023: Motivational Interviewing Highlights & Side Effects. Trial Name: NCT05617898 — N/A

Motivational Interviewing 2023 Treatment Timeline for Medical Study. Trial Name: NCT05617898 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are enrollment processes currently underway for this clinical experiment?

"As per the clinicaltrials.gov database, this trial has closed its recruitment process as of November 7th 2022; however, there are still 458 other studies actively seeking patients at this time. The trail was initially posted on January 1st 2023."

Answered by AI

Is it possible to enroll in this experiment?

"This scientific research is seeking 152 people with psychotic disorders, aged 18-35. Participation requirements include a DSM-5 diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (depressed type), taking second generation antipsychotics, an estimated premorbid IQ no less than 70 as assessed by the Wechsler Test for Adult Reading and adequate fluency in English to understand testing procedures. Additionally, those chosen must have corrected vision of at least 20/30 with no pacemakers or metal implants present."

Answered by AI

Are individuals who are 25 years or older accepted as participants in this research?

"This medical research necessitates that applicants are between 18 and 35 years of age. Separately, there exist 122 trials for those under the age of 18 and 274 studies available to participants over 65."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Determining the Role of Social Reward Learning in Social Anhedonia

Junghee Lee 2023. "Determining the Role of Social Reward Learning in Social Anhedonia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05617898.